Spots Global Cancer Trial Database for icos
Every month we try and update this database with for icos cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer | NCT03989362 | Cancer | Vopratelimab Ipilimumab | 18 Years - | Jounce Therapeutics, Inc. | |
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors | NCT02904226 | Cancer | JTX-2011 Nivolumab Ipilimumab Pembrolizumab | 18 Years - | Jounce Therapeutics, Inc. | |
A Study of XmAb23104 in People With Sarcoma | NCT05879185 | Sarcoma | XmAb23104 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer | NCT03989362 | Cancer | Vopratelimab Ipilimumab | 18 Years - | Jounce Therapeutics, Inc. | |
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors | NCT04319224 | Cancer | Vopratelimab Ipilimumab Nivolumab | 18 Years - | Jounce Therapeutics, Inc. |